

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-31 (canceled)

Claim 32 (new): A dosage form comprising 5 mg to 250 mg of a member selected from the set consisting of oxybutynin and its pharmaceutically acceptable salt, wherein said dosage form delivers said member from said dosage form at a substantially zero order rate of release over the period of about 24 hours.

Claim 33 (new): The dosage form according to Claim 32, wherein said salt is oxybutynin hydrochloride.

Claim 34 (new): The dosage form according to Claim 32, wherein said dosage form further comprises a member selected from the group consisting of hydroxypropylmethylcellulose, hydroxypropylethylcellulose, hydroxypropylbutylcellulose, and hydroxypropylpentylcellulose.

Claim 35 (new): The dosage form according to Claim 33, wherein said dosage form further comprises a member selected from the group consisting of hydroxypropylmethylcellulose, hydroxypropylethylcellulose, hydroxypropylbutylcellulose, and hydroxypropylpentylcellulose.

Claim 36 (new): The dosage form according to Claim 32, wherein said dosage form is a tablet.

Claim 37 (new): The dosage form according to Claim 33, wherein said dosage form is a tablet.

Claim 38 (new): The dosage form according to Claim 34, wherein said dosage form is a tablet.

Claim 39 (new): The dosage form according to Claim 35, wherein said dosage form is a tablet.

Claim 40 (new): A method for the management of incontinence in a patient, wherein the method comprises admitting orally into the patient a dosage form comprising 5 mg to 250 mg of a member selected from the set consisting of oxybutynin and its pharmaceutically acceptable salt, wherein said dosage form delivers said member from said dosage form to the patient at a substantially zero order rate of release over the period of about 24 hours.

Claim 41 (new): The method according to Claim 40, wherein said salt is oxybutynin hydrochloride.

Claim 42 (new): The method according to Claim 40, wherein said dosage form further comprises a member selected from the group consisting of hydroxypropylmethylcellulose, hydroxypropylethylcellulose, hydroxypropylbutylcellulose, and hydroxypropylpentylcellulose.

Claim 43 (new): The method according to Claim 41, wherein said dosage form further comprises a member selected from the group consisting of hydroxypropylmethylcellulose, hydroxypropylethylcellulose, hydroxypropylbutylcellulose, and hydroxypropylpentylcellulose.

Claim 44 (new): The method according to Claim 40, wherein said dosage form is a tablet.

Claim 45 (new): The method according to Claim 41, wherein said dosage form is a tablet.

Claim 46 (new): The method according to Claim 42, wherein said dosage form is a tablet.

Claim 47 (new): The method according to Claim 43, wherein said dosage form is a tablet.

Claim 48 (new): The method according to any one of Claims 40, 41, 42, 43, 44, 45, 46 or 47 wherein the incidence of side effects associated with oxybutynin treatment is reduced.